Cargando…

Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications

OBJECTIVE: Understanding public discourse on emergency use of unproven therapeutics is essential to monitor safe use and combat misinformation. We developed a natural language processing-based pipeline to understand public perceptions of and stances on coronavirus disease 2019 (COVID-19)-related dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Yining, Jiang, Hang, Lin, Shixu, Yang, Jie, Plasek, Joseph M, Bates, David W, Zhou, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278189/
https://www.ncbi.nlm.nih.gov/pubmed/35775946
http://dx.doi.org/10.1093/jamia/ocac114
_version_ 1784746143453806592
author Hua, Yining
Jiang, Hang
Lin, Shixu
Yang, Jie
Plasek, Joseph M
Bates, David W
Zhou, Li
author_facet Hua, Yining
Jiang, Hang
Lin, Shixu
Yang, Jie
Plasek, Joseph M
Bates, David W
Zhou, Li
author_sort Hua, Yining
collection PubMed
description OBJECTIVE: Understanding public discourse on emergency use of unproven therapeutics is essential to monitor safe use and combat misinformation. We developed a natural language processing-based pipeline to understand public perceptions of and stances on coronavirus disease 2019 (COVID-19)-related drugs on Twitter across time. METHODS: This retrospective study included 609 189 US-based tweets between January 29, 2020 and November 30, 2021 on 4 drugs that gained wide public attention during the COVID-19 pandemic: (1) Hydroxychloroquine and Ivermectin, drug therapies with anecdotal evidence; and (2) Molnupiravir and Remdesivir, FDA-approved treatment options for eligible patients. Time-trend analysis was used to understand the popularity and related events. Content and demographic analyses were conducted to explore potential rationales of people’s stances on each drug. RESULTS: Time-trend analysis revealed that Hydroxychloroquine and Ivermectin received much more discussion than Molnupiravir and Remdesivir, particularly during COVID-19 surges. Hydroxychloroquine and Ivermectin were highly politicized, related to conspiracy theories, hearsay, celebrity effects, etc. The distribution of stance between the 2 major US political parties was significantly different (P < .001); Republicans were much more likely to support Hydroxychloroquine (+55%) and Ivermectin (+30%) than Democrats. People with healthcare backgrounds tended to oppose Hydroxychloroquine (+7%) more than the general population; in contrast, the general population was more likely to support Ivermectin (+14%). CONCLUSION: Our study found that social media users with have different perceptions and stances on off-label versus FDA-authorized drug use across different stages of COVID-19, indicating that health systems, regulatory agencies, and policymakers should design tailored strategies to monitor and reduce misinformation for promoting safe drug use. Our analysis pipeline and stance detection models are made public at https://github.com/ningkko/COVID-drug.
format Online
Article
Text
id pubmed-9278189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92781892022-07-18 Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications Hua, Yining Jiang, Hang Lin, Shixu Yang, Jie Plasek, Joseph M Bates, David W Zhou, Li J Am Med Inform Assoc Research and Applications OBJECTIVE: Understanding public discourse on emergency use of unproven therapeutics is essential to monitor safe use and combat misinformation. We developed a natural language processing-based pipeline to understand public perceptions of and stances on coronavirus disease 2019 (COVID-19)-related drugs on Twitter across time. METHODS: This retrospective study included 609 189 US-based tweets between January 29, 2020 and November 30, 2021 on 4 drugs that gained wide public attention during the COVID-19 pandemic: (1) Hydroxychloroquine and Ivermectin, drug therapies with anecdotal evidence; and (2) Molnupiravir and Remdesivir, FDA-approved treatment options for eligible patients. Time-trend analysis was used to understand the popularity and related events. Content and demographic analyses were conducted to explore potential rationales of people’s stances on each drug. RESULTS: Time-trend analysis revealed that Hydroxychloroquine and Ivermectin received much more discussion than Molnupiravir and Remdesivir, particularly during COVID-19 surges. Hydroxychloroquine and Ivermectin were highly politicized, related to conspiracy theories, hearsay, celebrity effects, etc. The distribution of stance between the 2 major US political parties was significantly different (P < .001); Republicans were much more likely to support Hydroxychloroquine (+55%) and Ivermectin (+30%) than Democrats. People with healthcare backgrounds tended to oppose Hydroxychloroquine (+7%) more than the general population; in contrast, the general population was more likely to support Ivermectin (+14%). CONCLUSION: Our study found that social media users with have different perceptions and stances on off-label versus FDA-authorized drug use across different stages of COVID-19, indicating that health systems, regulatory agencies, and policymakers should design tailored strategies to monitor and reduce misinformation for promoting safe drug use. Our analysis pipeline and stance detection models are made public at https://github.com/ningkko/COVID-drug. Oxford University Press 2022-07-18 /pmc/articles/PMC9278189/ /pubmed/35775946 http://dx.doi.org/10.1093/jamia/ocac114 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
spellingShingle Research and Applications
Hua, Yining
Jiang, Hang
Lin, Shixu
Yang, Jie
Plasek, Joseph M
Bates, David W
Zhou, Li
Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications
title Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications
title_full Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications
title_fullStr Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications
title_full_unstemmed Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications
title_short Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications
title_sort using twitter data to understand public perceptions of approved versus off-label use for covid-19-related medications
topic Research and Applications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278189/
https://www.ncbi.nlm.nih.gov/pubmed/35775946
http://dx.doi.org/10.1093/jamia/ocac114
work_keys_str_mv AT huayining usingtwitterdatatounderstandpublicperceptionsofapprovedversusofflabeluseforcovid19relatedmedications
AT jianghang usingtwitterdatatounderstandpublicperceptionsofapprovedversusofflabeluseforcovid19relatedmedications
AT linshixu usingtwitterdatatounderstandpublicperceptionsofapprovedversusofflabeluseforcovid19relatedmedications
AT yangjie usingtwitterdatatounderstandpublicperceptionsofapprovedversusofflabeluseforcovid19relatedmedications
AT plasekjosephm usingtwitterdatatounderstandpublicperceptionsofapprovedversusofflabeluseforcovid19relatedmedications
AT batesdavidw usingtwitterdatatounderstandpublicperceptionsofapprovedversusofflabeluseforcovid19relatedmedications
AT zhouli usingtwitterdatatounderstandpublicperceptionsofapprovedversusofflabeluseforcovid19relatedmedications